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ABSTRACT 
Biomarkers are widely used not only as prognostic or diagnostic indicators, or as surrogate 
markers of disease in clinical trials, but also to formulate theories of pathogenesis. We 
identify two problems in the use of biomarkers in mechanistic studies. The first problem 
arises in the case of multifactorial diseases, where different combinations of multiple causes 
result in patient heterogeneity. The second problem arises when a pathogenic mediator is 
difficult to measure. This is the case of the oxidative stress (OS) theory of disease where the 
causal components are reactive oxygen species (ROS) that have very short half-lives. In this 
case, it is usual measure the traces left by the reaction of ROS with biological molecules, 
rather than the ROS themselves. Borrowing from the philosophical theories of signs, we look 
at the different facets of biomarkers and discuss their different value and meaning in 
multifactorial diseases and system medicine, to inform their use in patient stratification in 
personalized medicine. 
 
SIGNIFICANCE 
Biomarkers are widely used in medicine. This study focuses on the use of biomarkers in the 
formulation of mechanistic hypotheses and their clinical use. Starting from different 
philosophical theories of signs, the study highlights the importance of networks in their 
meaning and value. The study also views biomarkers as endowed or not with action (proxies 
or signs) and suggests a new perspective in the translational use of biomarkers in patient 
stratification and mechanistic studies. 
 
\body 
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INTRODUCTION 
Molecular biomarkers can be defined as substances whose levels correlate with some 
pathological process. They are used as diagnostic or prognostic indicators, and to monitor 
the progression of disease in clinical trials (surrogate biomarkers) but also to formulate 
theories of disease.  We recently discussed the problems related to the use of molecular 
biomarkers of OS (1, 2) in the context of the clinical translation of the OS theory of disease 
(3). The present paper attempts to develop a theoretical framework for defining the 
different types of biomarkers using those of OS or inflammation as examples.  
 
Inflammation and the cytokine theory of disease 
Inflammation is largely mediated by activation of a gene expression profile, largely mapping 
to the transcription factor NF-kB, including inflammatory cytokines, adhesion molecules and 
enzymes involved in the synthesis of prostaglandins and nitric oxide. The most recent 
breakthrough in this field was the identification of inflammatory cytokines that led to the 
approval of specific inhibitors of IL-1, IL-6, IL-17 and TNF for the therapy of several 
inflammatory diseases, particularly rheumatoid arthritis (RA). 
Following identification of TNF as an inflammatory mediator (4), the availability of specific 
assays for its measurement in biological fluids of patients with rheumatoid arthritis (RA) 
were instrumental in the translation of that hypothesis into the clinical arena (5) and the 
formulation of a “cytokine theory of disease” (6). Just 14 years after the original finding, 
anti-TNF antibodies were a top selling biological drug. 
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The oxidative stress theory of disease and the use of indirect biomarkers 
Oxidative stress is due to elevated levels of reactive oxygen species (ROS) (7). Since the 1956 
paper postulating a “free radical theory of aging” (8), OS has been implicated as a causal 
factor in many disease (9) but, unlike the cytokine theory of disease, this has not led to any 
significant therapeutic breakthrough.  
A major problem with the OS theory is that it is practically impossible to measure ROS in 
biological fluids because of their very short half-life, ranging from microseconds for 
superoxide and nanoseconds for hydroxyl radicals (10). This difficulty applies of course to 
the measurement of ROS in patients and their biological fluids or biopsies, while generation 
of ROS by cell cultured in vitro can be measured more accurately. 
This is reminiscent of high-energy physics, where the short life of subatomic particles is such 
that these are detected only though the traces they leave during their decay. Likewise, OS 
biomarkers include oxidation products of biological molecules  (11).  Unlike cytokines, we 
cannot measure ROS but we measure “signs” that stand for them instead, and in this paper, 
we try to look at biomarkers from the perspective of different philosophical theories of 
signs.  
To do so, we will first recapitulate some key aspects of the main theories on signs that might 
be relevant to our problem, and attempt to draw links and similarities with biomarkers of 
inflammation and OS and their use in formulating theories of disease. 
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Concepts arising from various theories of signs 
In the theory of signs of Charles Pierce (https://plato.stanford.edu/entries/peirce/), a sign is 
“something which stands to somebody for something in some respect or capacity” (12). For 
Pierce, a sign is a component of a triad along with the interpretant and the object, or the 
“thing“ the sign stands for. For instance, smoke is a sign for fire. If we (the interpretant) see 
smoke coming from behind a mountain, we assume that there is a wildfire somewhere (Fig. 
1).  
Pierce distinguishes different types of signs. While the smoke in Fig.1 is called an index, a 
street sign depicting a fire is also a sign that resembles, but is not physically related to, the 
object is an icon. A sign can stand for an event or an object, and one can distinguish 
different types of signs based on the relationship they have with the object. 
The linguist Ferdinand de Saussure saw the language as a system of signs, where signs are 
related to other signs within the system, which led him to develop the concept that signs 
have a meaning (signification) but also a value. For instance, the knight, in the game of 
chess is a sign and has a meaning, the gentleman/soldier. However, it has also a value, but 
to appreciate that we need to see the knight in relation to the network of the other pieces 
in the game, its position on the chessboard and the rules of the game. Although the 
difference between value and meaning in de Saussure is not completely clear, we suggest 
that, for the use we will make of this concept, we consider value as something related to 
quantity (justified in this by the fact that de Saussure used also the example of the face 
value of a coin). We will develop later this concept that signs have a value that depends on 
the interactions among them. 
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Floridi recently analysed the differences between signs and proxies (13). Floridi’s concept of 
proxy is different from that of Wittgenstein where “being proxy for” means “denoting”, 
focusing instead on signs that exert an action, and on the direction of this action. Let’s make 
the example of when, in Italian and French law, it’s the major who can perform a wedding, 
but a city councillor can act on behalf of the mayor. This has been defined as a vicarious 
relation, where P is acting for R (the mayor). However, the direction of the action is one 
way, from R to P; a wedding conducted by a councillor is perfectly valid, but if we shoot the 
councillor the mayor will not die: if this was the case, then the councillor would be a proxy 
for the mayor.  
This difference is outlined in Fig 2. 
What we want to retain here is that signs can be classified based on their functional 
relationship with the object, and that a proxy relationship goes both ways and you can 
interact on the proxy to affect the object it refers to. 
In this analysis, Floridi distinguishes further between two types of signs with a vicarious 
relation. Those that are also signs that refer to R, in the sense they have a semiotic 
relationship with R, and signs that can act on behalf of/replace R but do not refer to it. The 
latter are defined surrogates (such as a PIN pad is a surrogate for a traditional key as it can 
perform the same function to open a door, but has no resemblance to a physical key). 
Another concept that we would like to develop is that of the degrees of separations 
between the sign and the object they stand for, using again the example of smoke as a sign 
for fire.  If there is a fire behind a mountain, the park ranger will see the smoke from an 
observation tower and call the fire department. Let’s assume we are sitting in a café from a 
point from which we cannot see either the fire or the smoke. If we see several fire trucks 
 7 
with lights and sirens, we assume there is a fire, even if we can’t see smoke. Now, let’s say 
we are at home and we don’t live by the main road. We don’t see the fire, we don’t see the 
smoke and we can’t see the fire trucks but we hear several sirens going by; we can still 
assume that there is a fire somewhere. 
We could say that, in this system, while smoke is directly related to fire (in the previous 
scheme) while the passage of the fire trucks is a sign that is one degree of separation from 
the object fire. Likewise, the sound of sirens will be two degrees of separation from the fire. 
Fire --> smoke – (ranger on observation tower) --> fire trucks --> siren 
 
Importantly, the more are the degrees of separation from the object, the more the sign is 
ambiguous (less specific). The sign that is closest to the object, smoke, normally really 
means a fire. Four or five speeding fire trucks (one degree of separation) are a good 
indicator that there is a fire, but they may be there for an accident. Hearing several sirens 
(two degrees of separation) is not a very specific sign of a fire as they may be police cars or 
ambulances called for an accident. Thus, the degrees of separation between the object and 
the sign are important in the specificity of the signification.  
 
The examples of diabetes, inflammation and oxidative stress 
We will try to analyse two examples of molecular biomarkers used to define disease 
mechanisms, bearing in mind the points retained from the discussion above, particularly the 
concept of proxy and that of degrees of separation. 
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Let’s start with a simple example. At the origin of diabetes there is a lack of production of, 
or response to, insulin. As a result, blood glucose increases leading to a number of 
pathological consequences. The blood level of glucose is a diagnostic biomarker for 
diabetes. In 1976 Cerami and colleagues discovered that exposure to high blood glucose 
resulted in the formation of glycated haemoglobin (HbA1c; Fig. 3) (14). Both high levels of 
glucose and HbA1c are signs of diabetes. However, HbA1c is, for kinetics reasons, a better 
diagnostic biomarker (15), even if it is more distant (two degrees of separation) from the 
mechanism of disease. 
Let’s look at the same scheme from the perspective of the identification of the mechanism 
of disease, or its therapy. High glucose has pathological consequences, and lowering its 
levels is good for the patient. However, drugs specifically targeting HbA1c would not modify 
the disease. While it may be a good surrogate biomarker in developing anti-diabetic drugs, 
HbA1c is not a proxy and acting on it will not act on the disease.  In fact, some drugs, e.g. 
dapsone, reduce the levels of HbA1c, but this does not make diabetic patients better (16). 
A more complicated picture can be drawn for inflammatory diseases, such as rheumatoid 
arthritis (RA). To make our point, we have drawn an oversimplified scheme of the 
inflammatory network in RA, involving only few mediators (Fig. 4). In this scheme, 
autoimmunity induces Th17 cells that, through the cytokine IL-17, activate macrophages to 
produce inflammatory cytokines (IL-1, IL-6 and TNF).  The IL-1 produced by macrophages 
activated earlier is also a major inducer of IL-17. These will cause swelling or tissue damage, 
either directly or via prostaglandins such as PGE2. IL-6 also acts on the liver to induce acute-
phase proteins such as C-reactive protein (CRP) and fibrinogen, and decreasing the synthesis 
of albumin. 
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IL-17 is directly related to autoimmunity, one degree of separation, while IL-1 and TNF are 
two degrees of separation away, IL-6 both two and three, PGE2 and CRP four. Although the 
cytokines listed (IL-1, IL-6, IL-17, TNF) are elevated in RA patients(17), only CRP is an 
established biomarker of disease (18) and is used for both diagnosis and as a surrogate 
marker in clinical trials. 
In terms of disease mechanism, however, IL-17, IL-1, IL-6 and TNF are proxies. Acting on 
them we act on the disease, and antibodies that neutralize these cytokines are approved 
therapies for RA. On the other hand, CRP is normally viewed as a protective molecule and its 
absence, in animal models, is not protective against arthritis (19, 20); therefore, CRP can be 
considered a sign, possibly a surrogate, but not a proxy. 
Let us now consider OS.  According to its definition (7), OS occurs when the concentrations 
of reactive oxygen species (ROS) increase. One of the most reactive ROS is the hydroxyl 
radical (OH.) that reacts with lipids, to initiate a chain reaction called lipid peroxidation, and 
nucleic acids. Its short half-life forces us to use biomarkers that are the result of its 
interaction with those biological molecules, and we will consider two of them. 
Fig. 5A shows how OH., by initiating lipid peroxidation, results in the generation of 
malondialdehyde (MDA, probably the most used OS biomarker).  Another biomarker used as 
an indirect indication of OH. formation is 8-OH-guanosine (8-OH-G; Fig. 5B). From the point 
of view of the distance, MDA is at > 6 degrees of separation from OH (several chemical 
reactions are required), while 8-OH-G has only two degrees of separation. This distance 
raises the problem of the specificity of these biomarkers. In fact, MDA is not only produced 
by OH. but also during arachidonic acid metabolism, and is used as a marker of  
cyclooxygenase (21).  
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Another question is whether OS biomarkers can be proxies. The main problem with the OS 
theory of disease is the difficulty of measuring the causative agents, ROS, unlike the 
cytokine theory of disease or the germ theory of disease where cytokines and microbes can 
be measured in biological fluids. This means that none of the biomarkers of OS used in most 
of the studies are proxies. 
 
Mathematical and statistical method for the validation of mechanistic biomarkers and the 
problem of multicausality 
When novel biomarkers are proposed, they are usually measured in a cohort of patients 
compared with healthy people or patients with unrelated disease. Then, a statistical 
comparison of the levels  among two or more groups is done using the classical frequentist 
statistics, that calculates the probability that there is no difference between the two groups 
(the theoretical null hypothesis) (22). Another approach is to assess the probability that the 
biomarker levels correlate with the severity of a disease, a clinical score, or an outcome. The 
limitations of approaches based on the null hypothesis significance testing, with its 
dichotomization of evidence, have been discussed recently (23).  The size of the patient 
population investigated is also decided on the basis of conventional “power analysis”, 
usually designed to meet the goals of the classical significance testing (24). 
The problem of validating biomarkers that we can use to build theories of disease, be they 
proxies (such as TNF or IL-6) or just signs (such as CRP or 8-OH-G), is that while the usual 
statistical approach may be useful for surrogate biomarkers, we can apply it to mechanism 
biomarkers only for disease that have a single cause, while many diseases are multifactorial, 
a result of multiple causes.  This is typically represented by the so-called Rothman’s causal 
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pies (25). We could assume, for instance, that RA develops when a number of component 
causes add up to form a sufficient cause (the pie). However, the same disease could develop 
by a different combination of component causes to make a different sufficient cause.  
Oxidative stress has been implicated as a causal component in many diseases, including RA 
(9). Clearly, it must be a component cause because not all people with evidence of high OS 
develop RA. The question then arises, if OS is a slice in the causal pie for RA, is it a necessary 
component cause? That would mean that OS is always needed, for the disease to develop 
and, therefore, all patients with RA will have OS (in red, Fig.6A).  
However, it is also possible that OS is a component cause only in one of the many possible 
sufficient causes, an in this case OS will be present in some patients but not in others. In this 
case, not all the patients with RA will have OS but only those with one specific sufficient 
cause (Fig.6B). These two possibilities are represented along with the third possibility 
(Fig.6C), whereby OS is, alone, a sufficient cause of RA, and is present in all patients. 
If we measure biomarkers of OS in these patients, the classical statistical approach using the 
null hypothesis significance testing would only give a positive result in the case of 
mechanisms A and C. In the case depicted in panel B, if OS was implicated only in some 
patients, we would not find a significant difference in the level of biomarker in a cohort of 
patients compared to healthy controls, or a correlation with disease severity/outcome.  
Classical statistics has ways to analyze subpopulations of patients by stratification for 
covariates (e.g. gender, ethnicity, age etc.), but this would not help.  
What is needed here is to first validate that higher levels of a biomarker signify that OS is 
present in a specific patient, and then use that biomarker to identify those RA patients that 
have OS.  It is difficult to name a clinically-validated biomarker of OS because there are not 
 12 
clinical conditions where OS is present in all patients (although radiation toxicity and ozone 
toxicity would get close (26)). Considering the additional problem of lack of specificity, it 
would be appropriate to use a different approach. We need to confirm that, in each patient, 
higher ROS levels are produced by measuring several OS biomarkers: we need to 
disambiguate the meaning of a sign. Exactly as it happens when we disambiguate the 
meaning of words, we need to look at the context. If we read a paper where MDA is 
measured in a study on diet and OS, we know its meaning is as a biomarker of OS, while if 
the context is that of a drug acting on platelet activation, we can extrapolate that MDA is 
intended as a biomarker of arachidonate metabolism.  
In patients, to find the value of a biomarker, and to validate it as an indicator of OS, one 
approach to disambiguate its meaning could be to look at another OS biomarker - another 
sign in the same system. Thus, in biomarkers, we need to see them in the context of other 
biomarkers in the same system also to disambiguate their meaning, not just to appreciate 
their value. 
Along the line of “systems of signs” another possibility is that, before any statistical analysis, 
we visualize the data in a network, both to identify potential patient subpopulations and to 
disambiguate the meaning of the biomarkers measured.  
We performed a proof-of-principle analysis of the levels of various OS biomarkers in 
different diseases (2). The data, obtained from published literature, consisted in a 
spreadsheet with different diseases and, for each of them, the OS biomarker that was 
reported elevated in that disease. These data were analysed using hierarchical cluster 
analysis to visualize the similarities between different diseases in terms of pattern of OS 
biomarkers (2).  
 13 
A second type of visualization is based on a network analysis, originally used to identify the 
“diseasome”, by which different diseases are connected based on genetic risk factors, 
subsequently extended to protein-protein interactions (27-29). 
Using published data (2), we have created a disease network based on the common OS 
biomarkers, as described in the Methods section.  The result is shown in Fig.7, depicting the 
vicinity of diseases based on commonly elevated biomarkers. 
 
This type of analysis, applied to biomarkers related to different disease mechanisms 
(inflammation, OS, autoimmunity, viral antibodies etc.), could be used to identify diseases 
with common pathogenic mechanisms. It could also be applied to patients with a single 
disease to identify patients with different causal components in order to assign each patient 
to a hypothetical Rothman’s causal pie. This approach might then be followed by correlation 
analysis and classical significance testing to assess whether differences in the levels of 
biomarkers among different subgroups are robust. Along this line, a Bayesian latent 
hierarchical model has been proposed to identify meta-patterns of biomarkers in different 
cohort to facilitate hypothesis generation (30). 
 
Constraints in biomarker discovery 
Several conventions limit the study of biomarkers that identify causal components of 
disease. Statistical analysis based on the null hypothesis significance testing is a prerequisite 
for publication, in what has been defined a “lexicographic decision rule” (23). Funding 
agencies and ethical committees require a standard “research methodology” involving the 
use of power analysis to identify patients group size, tailored to satisfy classical significance 
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testing. For this reason, most of the studies on the “diseasome” published so far have been 
done analyzing published literature or databases rather than with laboratory or clinical 
studies.  
Another constraint is the drive to develop diagnostic/prognostic biomarkers to meet real 
clinical needs (such as diagnosis of cancer) or drug development needs, where surrogate 
biomarkers are used for the approval on new drugs instead of clinical outcomes (31). These 
constraints favour the discovery and validation of biomarkers that often do not provide 
indication on the mechanism of disease.  
Let’s go back once more to the OS theory of disease and the various possibilities outlined in 
Fig. 6. It is possible that OS is a causal component in RA, but it is also possible that it is a 
consequence of the disease, for instance secondary to inflammation or joint damage. If OS 
is a causal component and the disease has multiple causes as in Fig. 6B, we will not be able 
to find a statistically significant difference between a healthy group and a disease one. 
However, if OS was not a cause, but a result of the disease, i.e. a “biochemical symptom” or 
a causally-irrelevant by-product, then it would be present in all patients and, possibly, 
correlate with disease severity. Paradoxically, in multicausal disease, the more distant from 
the mechanism of disease is the biomarker, the more likely it is that it will be validated (and 
published) using classical significance testing. For instance, in Fig. 4, CRP is a better 
biomarker than IL-17 or TNF. Conventional statistical analysis and study design will favour 
the identification of causally-irrelevant prognostic biomarker even when the study was 
aimed at investigating the mechanism of disease. 
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Artificial intelligence, big data and the problem of the interpretant. 
For Pierce, the interpretant in Fig. 1 is a human mind and all the discussion in this paper 
implied a researcher/practitioner interpreting the meaning. If a biomarker is the carrier of a 
message, in medical semiotic “an observation that does not convey a message is not a sign” 
(32). However, -omics and big data may generate messages not intelligible to a human. An 
example is the use of gene expression profiling to identify arthritis patients that would 
benefit from biologicals. These studies analyzed the expression of tens of thousands of 
genes in drugs-responsive and non-responsive patients and identified algorithms, derived 
from the expression of up to 200 genes and cluster analysis, that correlate with drug 
responsiveness (33, 34). Only few of these genes will have a place in the theories about the 
mechanism of disease, because the function of many of them is not known, and the cluster 
will have no meaning for the human interpretant.  
This will require an entirely different approach and raises the challenging question on 
whether the theories of signs and the concept of “meaning”, and their application to 
biomarkers, need to be modified when interpreting big data. This is similar to the example 
cited by Evans on GPS navigation: “the physical world is translated into a database of 
instructions and distances, and interpreted by the application into a route to follow. . .   The 
application then presents the world back to the user in a mediated form . . .  which is used, 
to navigate the route “(35). Clearly an algorithm, or cluster of genes and transcripts, can 
represent a surrogate sign, as it can act on behalf of/replace the disease (and be used, for 
instance, as secondary outcomes in a clinical trial) without referring to it.  
While the focus on biomarkers generated by high-throughput techniques has been on their 
diagnostic and prognostic use, their use in building mechanistic theories of disease will 
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require a different theoretical and statistical approach. This is important in mechanism-
based patient stratification and in the translation of the concept of personalized medicine. 
 
METHODS 
The data were processed in GNU R and visualised as a graph. Thereafter, the graph was 
saved in a format that can be loaded into Gephi for exploratory analysis.  The source data 
are represented as a matrix where each row in the matrix represents whether each of the 
20 biomarkers indicate the presence of a disease.  In general, either a biomarker is elevated 
in a disease, according to the small sample of the literature analysed, or it does not.  The 
binary nature of these observations lend themselves to computing the similarity of diseases 
using a Jaccard index (36).  The Jaccard distance between diseases is normalised between 0 
and 1.  The more similarity between diseases the closer their Jaccard distance is to 0. The 
computed matrix of Jaccard distances is then transformed into a matrix of edge weights and 
presented using a force-directed graph layout algorithm (37).  In our graph layout, the 
diseases are visualised as graph vertices.  The edges of the graph are weighted with the 
inverse of their Jaccard distance.  Graph edges with a weight of 1 indicate a strong 
attraction between the vertices, whereas graph edges with a weight of 0 indicates no 
attraction between the vertices.  The graph layout is computed using the DrL algorithm and 
the results are saved to a Gephi file.  The visualization code is available at this URL:  
https://github.com/AidanDelaney/DiseaseViz 
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Figure Legends 
 
Fig.1. The semiotic triad 
Fig.2. Direction of activity in proxies 
Fig.3. Simplified scheme of the pathogenesis of diabetes 
Fig.4. Simplified pathogenesis of rheumatoid arthritis (pictures: Wikimedia commons) 
Fig. 5. Reactions leading to the formation of MDA (A) and 8-OH-G (B) 
Fig. 6. Different causal models for the OS theory of disease. Oxidative stress (in red) can be a component cause 
necessary but not sufficient (A) or not necessary (B). It can also be a sufficient cause of disease (C) 
Fig. 7. Disease vicinity based on OS biomarkers, based on data from (2). 
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